The current study evaluated a large cohort of high-risk AML patients with RUNX1–RUNX1T1 who underwent Allo-HSCT or Auto-HSCT to clarify the prognostic significance of different types of KIT mutations and RUNX1/RUNX1T1 quantification. This evidence concerns the gene RUNX1 and acute myeloid leukemia.